Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor Jun 08, 2016 8:00am EDT
Aptose To Release First Quarter Ended March 31, 2016 Financial Results and Hold Conference Call on May 10, 2016 May 02, 2016 8:00am EDT
Aptose To Release Fourth Quarter and Year End December 31, 2015 Financial Results and Hold Conference Call on March 29, 2016 Mar 14, 2016 8:00am EDT
Aptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference Feb 18, 2016 5:00pm EST
Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting Dec 03, 2015 8:00am EST
Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures Nov 20, 2015 7:30am EST
